ArticleInfectious diseases now2022
Bronchiolitis epidemics in France during the SARS-CoV-2 pandemic: The 2020-2021 and 2021-2022 seasons.
Article in Infectious diseases now, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of common respiratory viruses of infants with respiratory tract infections in European countries in the past decade: a systematic review and meta-analysis comparing between the pre-COVID-19, pandemic, and post-COVID-19 periods.European journal of pediatrics · 2026Pooled it
- Impact of COVID-19 Pandemic on Bronchiolitis Epidemiology in Greece.Medicina (Kaunas, Lithuania) · 2025Article
- Clinical epidemiology of community-acquired pneumonia in children before, during, and after the COVID-19 pandemic, and independent risk factors analysis for severe community-acquired pneumonia.Journal of global health · 2025Article
- How to assess the severity of bronchiolitis epidemics? Application of the Moving Epidemic Method in Nouvelle-Aquitaine, France from 2017 to 2023.BMC public health · 2025Article
- Distinct seasonality and increased respiratory failure in RSV patients < 2 years of age after emergence of SARS-CoV-2: data from the multicentric, prospective PAPI study.European journal of pediatrics · 2025Observational
- Effectiveness of nirsevimab in reducing hospitalizations in emergency departments due to bronchiolitis among infants under 3 months: a retrospective study.European journal of pediatrics · 2025Article
- Shifts in Respiratory Virus Epidemiology on Reunion Island From 2017 to 2023: Impact of COVID-19 Pandemic and Non-Pharmaceutical Interventions.Influenza and other respiratory viruses · 2025Article
- Analysis of BeyfortusCurrent issues in molecular biology · 2024Review
- Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023-January 2024.Influenza and other respiratory viruses · 2024Article
- Article
- Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic.JAMA network open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe described bronchiolitis epidemics during the 2020-2021 and 2021-2022 seasons in France and their interaction with the COVID outbreak. PATIENTS AND
methodsData on family physician (FP) visits, emergency department (ED) visits, hospitalizations for bronchiolitis for children˂2 years, and hospital virological data were analyzed and compared with previous seasons (2015-2020).
resultsThe 2020-2021 epidemic arrived very late, and its impact was lower than in previous seasons (2015-2020) (FP visits: -23%, ED visits: -38%, and hospitalizations: -30%). The 2021-2022 epidemic started early (week 40) and lasted for a relatively long time (13 weeks). The impact was higher than in 2015-2020 (FP visits: +13%, ED visits: +34%, hospitalizations: +28%).
conclusionFindings from the 2020-2021 epidemic may be linked to the implementation of non-pharmaceutical COVID-19 prevention measures. For 2021-2022, findings may be linked to an "immunity debt" resulting from the lower impact of the previous season.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.